|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||24.05 - 24.94|
|52 Week Range||23.09 - 51.11|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 08, 2023 - May 12, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ARWR
PASADENA, Calif., March 20, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union.
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders might be concerned after seeing the share price drop 12...
PASADENA, Calif., March 03, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston.